Dr Ho was recognised by the Singapore-MIT Alliance (SMA) in 2010 for his novel discovery, and he was awarded the SMA Graduate Fellowship for his PhD studies at NUS.
For his postgraduate studies, Dr Ho built upon his findings to better understand the therapeutic properties and molecular mechanisms of artesunate under the supervision of Assoc Prof Fred Wong.
The NUS team studied the therapeutic effects of artesunate against oxidative stress and oxidative lung damage which are major inflammatory events that contribute to the severity of asthma attacks. They found that artesunate could better prevent oxidative lung damage, a major molecular inflammatory event in asthmatic lungs, than clinically-used corticosteroid, dexamethasone.
Their collective results revealed that artesunate can be used to better control asthma, with improved outcomes and lesser adverse effects than currently available drugs. As long term usage of steroids may induce many potential side effects in asthmatic patients, the significance of this study suggests that the patients may eventually be able to adopt artesunate as a safer and more effective alternative to control their asthma.
The next step
Moving forward, the team led by Assoc Prof Wong will further explore the therapeutic and pharmacological effects of artesunate for asthma, as well as for other medical conditions. They also intend to work with industry partners to test the effects of artesunate on asthmatic patients.
Dr Ho is also furthering his research as a Research Fellow at the Saw Swee Hock School of Public Health at NUS, where he is investigating the molecular mechanisms of artesunate, and hopes to discover more beneficial effects of artesunate and accelerate the adoption of this drug for clinical tests.
|Contact: Carolyn Fong|
National University of Singapore